FDA Brief

Warning letters Drugs

FDA warning letter to

Frenda Corporation

High riskIssued Feb 15, 2023Posted Mar 14, 2023Division of Pharmaceutical Quality Operations II

FDA found Frenda made OTC alcohol and hand sanitizer under insanitary conditions with industrial chemical cross-contamination risk.

What happened

FDA inspected Frenda’s drug manufacturing facility in Trujillo Alto, Puerto Rico, from July 26 to August 1, 2022. Investigators observed insects in bottle and cap supplies, filthy conditions, rust-like residues and dirty seals on filling equipment, and shared equipment and areas with industrial chemicals. FDA also found inadequate water control, component testing, quality unit oversight, and finished product testing.

What FDA found

  1. Drug products were made, packed, or held under insanitary conditions, including insects in bottle and cap supplies and filthy facility conditions.

    FD&C Act section 501(a)(2)(A), 21 U.S.C. 351(a)(2)(A)
  2. The firm used the same equipment and areas for OTC drugs and industrial cleaning chemicals, creating cross-contamination and mix-up risks.

    21 CFR 211.42(c)
  3. Filling equipment was in disrepair, with rust-like residues and dirty, damaged product-contact seals, and cleaning procedures and logs were missing.

    21 CFR 211.67(a)
  4. The water system was not validated or routinely monitored for chemical and microbiological quality.

    21 CFR 211.100(a) and 211.100(b)
  5. The firm did not test each component lot for identity and relied on supplier certificates without verifying them, including for ingredients such as isopropyl alcohol, ethanol, and glycerin.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  6. The quality unit did not ensure adequate procedures, stability testing, annual product reviews, batch records, investigations, and full finished-product testing before release.

    21 CFR 211.22, 211.165, 211.166(a), 211.180(e), 211.188, 211.192

What FDA wants

FDA asks Frenda to respond in writing within 15 working days and confirm whether it intends to resume drug manufacturing, and to notify FDA before resuming. If it resumes, FDA says it should engage a qualified consultant to perform a comprehensive six-system audit for current good manufacturing practice (CGMP) compliance.

Who should pay attention

  • retailers and distributors selling OTC alcohol and hand sanitizer
  • companies that buy OTC drug products from this manufacturer
  • quality teams at drug manufacturers that share equipment with industrial chemicals

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. ABC Food Corp

    ABC Food Corp's ready-to-eat rice noodles and tofu were made without required hazard analysis and preventive controls.

    High risk
  3. Rama Food Manufacture Corp.

    FDA warns Rama Food Manufacture after inspections found insanitary conditions and preventive-control failures at its California ready-to-eat rice noodle plants.

    High risk
  4. Lewis Sausage Company Inc.

    FDA found Salmonella and Listeria in contract-made pet food from Lewis Sausage and says its pathogen controls are inadequate.

    High risk